The Indianapolis-based drugmaker is citing an FDA inspection in Houston as part of a complaint it filed in late July against ...

Eli Lilly & Company (NYSE:LLY) ranks among the best low volatility stocks to buy according to analysts. On July 11, ...

Europe has given limited approval to Lilly's Alzheimer's drug, President Trump has announced a trade deal with the EU, Delta ...

Eli Lilly's acquisition of Vere Therapeutics promises to revolutionize cardiovascular care with innovative one-time gene ...

Eli Lilly's appeal of a decision by the EMA's human medicines committee not to approve its Alzheimer's disease therapy ...

Eli Lilly is walking through the Gate, inking a deal worth up to $856 million with a biotech aiming to build out a new ...

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

Finally, don't discount legal challenges to the president's tariffs. An argument could be made that pharmaceutical products ...

Eli Lilly's biggest growth driver, tirzepatide, will continue facing scrutiny from investors and analysts. The company's oral ...